Biotechnology News

LA JOLLA, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock...

Sabrina Kuttruff-Coqui appointed Chief Executive Officer, Joachim Koch appointed Chief Scientific and Development Officer and Andreas Muehler joining as Chief Medical OfficerExpanded leadership team...

Company announcement no. 34 - 2608 September 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as...

– Verekitug, 100 mg dosed every 12 weeks, reduced AAER by 56% compared to placebo in patients with severe asthma – – Verekitug also delivered clinically meaningful improvements in lung function...

PannTheraPi receives ANSM approval to advance PTI5803 into Phase 2a for focal cortical dysplasia, a rare and severe form of epilepsy

PannTheraPi obtient l’approbation de l’ANSM pour l’entrée en Phase 2a de PTI5803 dans la dysplasie corticale focale, une forme rare et sévère d’épilepsie.

First-in-class oral ERAP1 inhibitor GRWD0715 dosed in first axSpA participants; clean SAD safety data and US patent granted

Informations relatives au nombre total de droits de vote et d’actions composant le capital

COPENHAGEN, Denmark, September 7, 2026 – Bavarian Nordic A/S (OMX: BAVA) announces transactions under the share buy-back program launched on September 1, 2026, under which the Company will repurchase...

KØBENHAVN, Danmark, 7. september 2026 – Bavarian Nordic A/S (OMX: BAVA) offentliggør transaktioner under aktietilbagekøbsprogrammet, der blev iværksat den 1. september 2026, hvorunder selskabet vil...